Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang Wolwo Bio-Pharma Gains 94% Post-IPO

publication date: Jan 24, 2014
Zhejiang Wolwo Bio-Pharmaceutical completed a very successful IPO this week, a 506 million RMB ($83.7 million) transaction that listed the company on the Shenzhen exchange. It was one of eight China companies to become publicly owned after China shut down the IPO process for 14 months. Regulators revamped the country’s IPO process to make it more market oriented. Wolwo finished the week with a strong 94% gain. After pricing at 20.05 RMB, it climbed to 38.81 RMB. More details....

Stock Symbol: (SHE: 300357)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here